Zhong-Yin Zhang

Affiliations: 
Biochemistry and Molecular Biology Indiana University, Bloomington, Bloomington, IN, United States 
Area:
Biochemistry, Analytical Chemistry, Molecular Biology
Google:
"Zhong-Yin Zhang"

Children

Sign in to add trainee
Jinpeng Sun grad student 2001-2006 (Neurotree)
Chad D. Walls grad student 2012 Indiana University Bloomington
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Dong J, Jassim BA, Milholland KL, et al. (2024) Development of Novel Phosphonodifluoromethyl-Containing Phosphotyrosine Mimetics and a First-In-Class, Potent, Selective, and Bioavailable Inhibitor of Human CDC14 Phosphatases. Journal of Medicinal Chemistry
Chen H, Bai Y, Kobayashi M, et al. (2023) PRL2 phosphatase promotes oncogenic KIT signaling in leukemia cells through modulating CBL phosphorylation. Molecular Cancer Research : McR
Dong J, Miao J, Miao Y, et al. (2023) Small Molecule Degraders of Protein Tyrosine Phosphatase 1B and T-Cell Protein Tyrosine Phosphatase for Cancer Immunotherapy. Angewandte Chemie (International Ed. in English). e202303818
Bai Y, Yu G, Zhou HM, et al. (2022) PTP4A2 promotes lysophagy by dephosphorylation of VCP/p97 at Tyr805. Autophagy. 1-20
Zhu P, Wu X, Zhang RY, et al. (2022) An Integrated Proteomic Strategy to Identify SHP2 Substrates. Journal of Proteome Research
Gebregiworgis T, Kano Y, St-Germain J, et al. (2021) The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. Nature Communications. 12: 6274
Krabill AD, Zhang ZY. (2021) Functional interrogation and therapeutic targeting of protein tyrosine phosphatases. Biochemical Society Transactions. 49: 1723-1734
Xu YF, Chen X, Yang Z, et al. (2021) PTP-MEG2 regulates quantal size and fusion pore opening through two distinct structural bases and substrates. Embo Reports. e52141
Chen H, Libring S, Ruddraraju KV, et al. (2020) SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer. Oncogene
Zhu G, Xie J, Kong W, et al. (2020) Phase Separation of Disease-Associated SHP2 Mutants Underlies MAPK Hyperactivation. Cell
See more...